News | March 11, 2024
Briefs: Zydus Lifesciences and Rainbow Children's Medicare
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
The validations confirm the completion of the applications and commence the scientific review process
The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
ANVISA issues CGMP to Concord Biotech’s Unit I
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
This agreement paves the way for the introduction of YESAFILI into the Canadian market
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Subscribe To Our Newsletter & Stay Updated
